EGFR and non-small cell lung carcinoma: A possible explanation for this observation could be that in EGFR wild type NSCLC, signaling pathways other than the MAPK/ERK pathway, such as the signal transducer and activator of transcription 3 (STAT3) pathway [17] or the phosphoinositide 3-kinase (PI3K) pathway [18], play a central role.